Inclusion Criteria:

- Confirmed MDS (RA, RARS, RAEB, RAEB-T) or CMML according to FAB classification.

- Platelet transfusion dependence (requiring 1 to 8 platelet transfusion events every 4
week period (Day 84 to Day 57, Day 56 to Day 29, and Day 28 to Day 1) over an
8-week retrospective and 4-week prospective screening period).

- The individual number of platelet transfusion events during the three 4-weekly
periods (Day 84 to Day -57; Day -56 to Day 29; Day -28 to Day -1) must not differ
by greater more than 2 from the average number of platelet transfusion events during
the 12 week screening period.

- If the subject is RBC transfusion dependent, the number of RBC transfusion events
during the three 4-weekly periods (Days -84 to -57; Day -56 to Day 29 and Day -28 to
Day -1) must not differ by more than 2 from the average number of RBC transfusion
events during this 12 week screening period.

ECOG PS 0-2.

Exclusion Criteria:

- Subjects with chemotherapy/radiotherapy-associated secondary MDS.

- <12 Weeks (prior to Day-1 Randomization) from any investigational drug use, any
chemotherapy, radiotherapy, immunotherapy and any other treatment or MDS/CMML other
than best supportive care.

- Hx of bone-marrow or peripheral stem-cell transplantation or treatment with donor
lymphocyte infusion.

- Hx of AML.

- Known hx of immune thrombocytopenic purpura.

- Marked baseline prolongation of QTc interval, CTCAE Grade >=1.

- Use of ketokonazole within 72 hours prior to study drug administration.